Since IL-17 signaling is also implicated in the pathophysiology of Crohn’s disease (CD) [31] and systemic juvenile idiopathic arthritis (SJIA) [32], we evaluated brodalumab repositioning potential for these diseases. Here, IL17A is linked to Crohn disease.